Companies › iRegene Therapeutics
1 active drug program in 4 registered trials: 4 Phase 1; Neurology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NouvNeu001 | – | Phase 1 | Early-onset Parkinson's Disease; Parkinson Disease; Multiple System Atrophy - Parkinsonian Subtype (MSA-P) | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06608355 | NouvNeu001 | Phase 1 | Early-onset Parkinson's Disease | Neurology | Mar 2027 |
| NCT07102342 | NouvNeu001 | Phase 1 | Parkinson Disease | Neurology | Sep 2027 |
| NCT07289477 | NouvNeu001 | Phase 1 | Multiple System Atrophy - Parkinsonian Subtype (MSA-P) | Neurology | Oct 2027 |
| NCT06167681 | NouvNeu001 | Phase 1 | Parkinson Disease | Neurology | Jul 2029 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.